Fennec Pharmaceuticals Inc. (RV41)

Overview

Fennec Pharmaceuticals Inc. is a prominent biopharmaceutical company based in the United States, engaged in the development and commercialization of specialized therapies. Originally established as Adherex Technologies Inc., the company underwent a significant rebranding in September 2014, adopting the name Fennec Pharmaceuticals Inc. This rebranding reflects its evolution and dedicated focus on addressing specific medical needs. Since its inception in 1996, Fennec Pharmaceuticals has positioned itself in the Research Triangle Park, North Carolina, leveraging the region's rich resources in research and development. The company primarily targets pediatric cancer patients, aiming to mitigate the adverse effects associated with platinum-based chemotherapy treatments.

Products and Services

• PEDMARK:

  This leading product candidate by Fennec Pharmaceuticals Inc. is a novel formulation of sodium thiosulfate designed specifically for the prevention of platinum-induced ototoxicity in pediatric cancer patients. Platinum-based chemotherapies, while effective in treating cancer, often come with the severe side effect of ototoxicity—damage to the ear that can result in hearing loss. PEDMARK represents a significant advancement in the care and quality of life for young cancer patients, addressing an unmet need in pediatric oncology. The distribution of this product is strategically implemented through collaborations with regional pediatric oncology specialists and medical science liaisons, ensuring that the benefits of PEDMARK reach the patients in need effectively.